A study of M254 (Hyper-sialylated IVIg)

Trial Profile

A study of M254 (Hyper-sialylated IVIg)

Phase of Trial: Phase I

Latest Information Update: 08 May 2017

At a glance

  • Drugs M-254 (Primary)
  • Indications Autoimmune disorders; Inflammation
  • Focus Adverse reactions
  • Most Recent Events

    • 08 May 2017 New trial record
    • 02 May 2017 According to a Momenta Pharmaceuticals media release, company is planning to initiate clinical trial in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top